Tuesday, April 07, 2020 11:28:59 AM
CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference
ROCKVILLE, Md. and BEIJING, April 7, 2020 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Solebury Trout Virtual Global Healthcare Series. During the 25-minute presentation, participants will be able to submit questions electronically with answers provided by the discretion of the company on an individual basis afterwards. Details are as follows:
Date/Time: Tuesday, April 7, at 11:00a.m./p.m. EDT
To access the presentation, please login at: https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36850/indexl.html
Webcast archive: 24 hours following the presentation an archive of the event will be available on the Company’s website at https://www.casipharmaceuticals.com/
ROCKVILLE, Md. and BEIJING, April 7, 2020 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Solebury Trout Virtual Global Healthcare Series. During the 25-minute presentation, participants will be able to submit questions electronically with answers provided by the discretion of the company on an individual basis afterwards. Details are as follows:
Date/Time: Tuesday, April 7, at 11:00a.m./p.m. EDT
To access the presentation, please login at: https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36850/indexl.html
Webcast archive: 24 hours following the presentation an archive of the event will be available on the Company’s website at https://www.casipharmaceuticals.com/
Recent CASI News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/03/2026 02:00:21 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/26/2026 01:09:32 PM
- CASI Pharmaceuticals to be delisted from Nasdaq effective Wednesday • IH Market News • 02/25/2026 03:29:39 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/25/2026 02:10:17 PM
- CASI Pharmaceuticals Receives the Delisting Decision From the Nasdaq Hearings Panel • ACCESS Newswire • 02/25/2026 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/20/2026 02:00:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/19/2026 02:00:37 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/10/2026 02:00:14 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/22/2026 02:00:14 PM
- CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR) • ACCESS Newswire • 01/15/2026 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/13/2026 02:00:07 PM
- CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia • ACCESS Newswire • 01/12/2026 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/23/2025 09:15:44 PM
- CASI Pharmaceuticals Receives Extension from Nasdaq to Meet Listing Requirements • ACCESS Newswire • 12/23/2025 09:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/11/2025 02:15:09 PM
- CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing • ACCESS Newswire • 12/11/2025 02:00:00 PM
- CASI Pharmaceuticals Announces Results from CID-103 Immune Thrombocytopenia Study at the 67th American Society of Hematology (ASH) Annual Meeting • ACCESS Newswire • 12/08/2025 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/19/2025 02:15:18 PM
- CASI Pharmaceuticals Announces Changes in Board Governance • ACCESS Newswire • 11/19/2025 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/14/2025 09:30:14 PM
